Skip to content
Review Open access

Improving recombinant protein productivity in CHO cells via multi-omics data integration

Aug 2026 · Bioresources and Bioprocessing · Vol 13 · 0 citations · 252 references
Medicine

TL;DR

This review first summarizes the methodologies and advances in CHO omics research, including genomics, transcriptomics, proteomics, metabolomics, metabolomics, and epigenomics, and examines contemporary approaches to integrate and analyze multi-omics data in CHO cells.

Abstract

Chinese hamster ovary (CHO) cells represent the dominant host system for the production of recombinant therapeutic proteins. In recent decades, extensive research has focused on process/media optimization and cell line engineering to improve both the productivity and quality of biopharmaceutical proteins produced in CHO cells. Nevertheless, the inherent complexity of biological pathways and the heterogeneous cellular responses to different environmental conditions have posed substantial challenges to traditional methodologies. Recent advances in omics technologies have enabled comprehensive characterization of CHO cell physiology, providing multidimensional molecular and phenotypic insights that facilitate the enhancement of recombinant protein production. This review first summarizes the methodologies and advances in CHO omics research, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics. It then examines contemporary approaches to integrate and analyze multi-omics data in CHO cells. The review further elucidates how these multi-omics datasets can be strategically applied across various developmental stages, including cell line selection, genetic engineering, expression vector design, and bioprocess optimization. Finally, we explore the transformative potential of integrating multi-omics with artificial intelligence and discuss promising future research directions in CHO cell studies. These emerging paradigms offer novel opportunities for data-driven cell engineering and bioprocess optimization in CHO-based biomanufacturing.

Read PDF

Similar papers

Open access Sep 2026

Bridging Academic Insights and Industrial Practices: Upstream Process Development in Mammalian Cell-Based Biopharmaceutical Production

Biopharmaceuticals, particularly those produced using mammalian cell systems, have reshaped modern therapeutic approaches by enabling the production of complex and efficacious recombinant proteins. This study provides a comprehensive analysis of upstream process development strategies in mammalian cell-based biopharmac...

Buğrahan Regaip Kilinç, Oguzhan Ustun, Neda Abadian et al. · 0 citations
Review Oct 2026

The historical evolution of CHO cell line development for biologics production: 60 years and still counting.

Chinese Hamster Ovary (CHO) cells have played a central role in the production of therapeutic proteins since their initial isolation in the 1950s. Over the decades, scientific innovations have transformed CHO cells into the powerhouse of the biopharmaceutical industry. From rudimentary culture conditions and random int...

Juergen Fieder, Stefan Schneider, Simon Fischer · 0 citations
Open access Sep 2026

SEC-seq reveals translation-focused metabolic strategies for high IgG productivity in clonal CHO cells.

Chinese hamster ovary (CHO) cells are the dominant host for therapeutic protein production, yet intra- and inter-clonal heterogeneity in manufacturing phenotypes, and the underlying metabolic and secretory circuitry, remain poorly defined at single-cell resolution. Using secretion encoded single-cell sequencing (SEC-se...

Jasmine Tat, Fides D. Lay, Jennitte L. Stevens et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.